



CORAL LABORATORIES LTD

AN ISO 9001: 2008 CERTIFIED ORGANIZATION



Registered Office: 3-B, Patanwala Industrial Estate, LBS Marg, Opp. Shreyas Cinema, Ghatkopar (West), Mumbai-400086

CIN: L24231MH1997PLC422233

Ph. No.: 022-25008208/25005245/46, E-mail: accounts@corallab.com, Website: www.corallab.com

November 14, 2025

To  
The Manager  
Corporate Relations Department,  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400 001

**Scrip Code – 524506**

Dear Sir/Madam,

**Sub: Outcome of the Board Meeting held on November 14, 2025, pursuant to Regulation 30 (Read with Part A of Schedule III) the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")**

In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable provisions, the Board of Directors of the Company in its meeting held on Friday, 14th November 2025 at the Corporate Office of the Company situated at 3B, Patanwala Compound, Opp. Shreyas Cinema, L.B.S. Marg, Ghatkopar (W), Mumbai- 400086, has inter alia considered and approved:

1. The Unaudited Standalone Financial Results along with Statement of Asset & Liabilities and Cash Flow Statement for the quarter and half year ended September 30, 2025 and took note of the Limited Review Report submitted by S C Mehra & Associates LLP, Statutory Auditor of the Company.

In view of the above, we enclose herewith:

- Unaudited Standalone Financial Results along with statement of Asset & Liabilities and Cash Flow Statement.
- Limited Review Report.

The results will be uploaded on the Company's website <http://www.corallab.com> will be published in Freepress Journal (English) and Navshakti (Marathi) newspapers as per Regulation 30 & 47 under SEBI (Listing Obligation and Disclosure Requirements), Regulations 2015.

This is for your information and records.

The Meeting commenced at 2:30 P.M. and was concluded by 5.30 P.M. on the same day.

Yours sincerely,

**For CORAL LABORATORIES LIMITED**

**Dhwani Desai**  
**Company Secretary & Compliance Officer**

**Place:** Mumbai

**Encl:** As above

**Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company, pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

To,  
**The Board of Directors**  
**Coral Laboratories Limited**

1. We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **CORAL LABORATORIES LIMITED** ("the Company"), for the quarter ended September 30, 2025, and the year to date results for the period 1 April 2025 to 30 September 2025 ("the statement") being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the Indian Accounting Standard 34 "Interim Financial reporting" ("Ind AS 34") as prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the entity' issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The Limited Review for the quarter ended June 30, 2025, was conducted by the previous auditors, **M/s M. A. Parekh & Associates**, who retired at the conclusion of the Annual General Meeting held on September 26, 2025. We have been appointed as the Statutory Auditors of the Company with effect from the quarter ended September 30, 2025.

**S C MEHRA & ASSOCIATES LLP**

**Head Office:** Office No. 42, 1st Floor, Singh Estate No. 3, Near Mrinaltai Gore Flyover, Next to D'Mart, Ram Mandir (West),  
Mumbai - 400 104, Maharashtra, India.

Mob. : +91 9820060260 • Email: [sc.mehra@scmassociates.in](mailto:sc.mehra@scmassociates.in)

**Branches:** Ahmedabad • Bengaluru • Bhopal • Delhi NCR • Hyderabad • Jaipur • Jodhpur • Thane

The corresponding figures for the quarter and half year ended September 30, 2024 and for the year ended March 31, 2025, as well as the Limited Review for the quarter ended June 30, 2025, were reported upon by the predecessor auditors. Their reports expressed an unmodified opinion on those periods. Our report is not modified in respect of this matter.

**For S C Mehra & Associates LLP**  
**Chartered Accountants**  
**(FRN No. 106156W/W100305)**



**Suresh Mehra**

Partner

M No. 039730

Place: Mumbai

Date: 14<sup>th</sup> November, 2025

UDIN: 25039730BMHZZG2577

**S C MEHRA & ASSOCIATES LLP**

**Head Office:** Office No. 42, 1st Floor, Singh Estate No. 3, Near Mrinaltai Gore Flyover, Next to D'Mart, Ram Mandir (West),  
Mumbai - 400 104, Maharashtra, India.

Mob. : +91 9820060260 • Email: [sc.mehra@scmassociates.in](mailto:sc.mehra@scmassociates.in)

**Branches:** Ahmedabad • Bengaluru • Bhopal • Delhi NCR • Hyderabad • Jaipur • Jodhpur • Thane





# CORAL LABORATORIES LTD

AN ISO 9001: 2008 CERTIFIED ORGANIZATION



REGD. OFFICE : #3B, Patanwala Compound, Opp. Shreyas Cinema, L.B.S. Marg, Ghatkopar (West), Mumbai - 400 086. India  
Tel. : +91-22-2500 5245, 2500 8208, 2500 5246. • Fax : +91-22-2500 4893. • E-mail : accounts@corallab.com • Website : www.corallab.com  
CIN NO. L24231MH1997PLC422233

## Statement of Standalone Unaudited Financial Results for the Quarter and Half Year ended 30th September 2025

(₹ in Lakhs) (Except Figures in EPS)

| Sr.<br>No | Particulars<br>(Refer Notes Below)                                                                                          | Quarter Ended  |                |                | Half Year ended |                | Year Ended      |
|-----------|-----------------------------------------------------------------------------------------------------------------------------|----------------|----------------|----------------|-----------------|----------------|-----------------|
|           |                                                                                                                             | 30.09.2025     | 30.06.2025     | 30.09.2024     | 30.09.2025      | 30.09.2024     | 31.03.2025      |
|           |                                                                                                                             | (Unaudited)    | (Unaudited)    | (Unaudited)    | (Unaudited)     | (Unaudited)    | (Audited)       |
| 1         | <b>Income</b>                                                                                                               |                |                |                |                 |                |                 |
|           | (a) Revenue from Operations                                                                                                 | 1903.48        | 1882.14        | 3222.87        | 3785.63         | 6388.45        | 11500.53        |
|           | (b) Other Income                                                                                                            | 270.87         | 204.81         | 254.32         | 475.68          | 410.43         | 910.86          |
| 2         | <b>Total income</b>                                                                                                         | <b>2174.35</b> | <b>2086.96</b> | <b>3477.20</b> | <b>4261.31</b>  | <b>6798.88</b> | <b>12411.39</b> |
| 3         | <b>Expenses</b>                                                                                                             |                |                |                |                 |                |                 |
|           | (a) Cost of Materials consumed                                                                                              | 730.61         | 833.30         | 1596.57        | 1563.92         | 2777.00        | 4814.32         |
|           | (b) Purchase of stock-in-trade                                                                                              | 80.97          | 81.89          | 27.31          | 162.86          | 97.52          | 156.15          |
|           | (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade                                           | (56.54)        | (41.46)        | (68.80)        | (98.00)         | 23.82          | 331.50          |
|           | (d) Employee benefits expense                                                                                               | 369.93         | 342.12         | 393.13         | 712.06          | 752.12         | 1473.71         |
|           | (e) Depreciation and amortisation expense                                                                                   | 45.22          | 45.32          | 50.90          | 90.80           | 100.30         | 201.06          |
|           | (f) Financial Cost                                                                                                          | 10.27          | 5.79           | 1.13           | 16.06           | 3.97           | 9.76            |
|           | (g) Other expenses                                                                                                          | 284.62         | 448.06         | 623.97         | 732.68          | 1013.75        | 2100.91         |
|           | <b>Total Expenses</b>                                                                                                       | <b>1465.09</b> | <b>1715.03</b> | <b>2624.22</b> | <b>3180.37</b>  | <b>4768.47</b> | <b>9087.41</b>  |
| 4         | <b>Profit from operations before exceptional items and tax</b>                                                              | <b>709.27</b>  | <b>371.93</b>  | <b>852.98</b>  | <b>1080.94</b>  | <b>2030.41</b> | <b>3323.98</b>  |
| 5         | Exceptional Items (Provision of Income tax of earlier year)                                                                 | (32.25)        | 0.00           | -              | (32.25)         | -              | 76.96           |
| 6         | <b>Profit from ordinary activities before tax</b>                                                                           | <b>741.51</b>  | <b>371.93</b>  | <b>852.98</b>  | <b>1113.18</b>  | <b>2030.41</b> | <b>3247.02</b>  |
| 7         | <b>Tax expense</b>                                                                                                          |                |                |                |                 |                |                 |
|           | (a) Current Tax                                                                                                             | 159.00         | 115.00         | 213.00         | 274.00          | 508.00         | 833.00          |
|           | (b) Deferred Tax                                                                                                            | 0.50           | 0.50           | 2.00           | 1.00            | 4.00           | -1.54           |
| 8         | <b>Profit from Continuing Operation</b>                                                                                     | <b>582.01</b>  | <b>256.43</b>  | <b>637.98</b>  | <b>838.18</b>   | <b>1518.41</b> | <b>2415.56</b>  |
| 9         | <b>Profit From discontinuing operations</b>                                                                                 |                |                |                |                 |                |                 |
| 10        | <b>Profit for the period</b>                                                                                                | <b>582.01</b>  | <b>256.43</b>  | <b>637.98</b>  | <b>838.18</b>   | <b>1518.41</b> | <b>2415.56</b>  |
| 11        | <b>Other Comprehensive Income</b>                                                                                           |                |                |                |                 |                |                 |
| A         | i) Items that will not be reclassified to profit and loss                                                                   | -212.85        | 563.15         | 284.10         | 350.30          | 1,158.11       | 26.80           |
|           | ii) Income tax relating to income that will not be reclassified to profit and loss                                          | -              | -              | -              | -               | -              | -               |
| 12        | <b>Total Comprehensive income for the period (Comprising profit and loss and other Comprehensive Income for the period)</b> | <b>369.16</b>  | <b>819.58</b>  | <b>922.08</b>  | <b>1188.48</b>  | <b>2676.52</b> | <b>2442.37</b>  |
| 13        | <b>Paid up Equity Share Capital (Face Value Rupees 10 per share)</b>                                                        | <b>357.26</b>  | <b>357.26</b>  | <b>357.26</b>  | <b>357.26</b>   | <b>357.26</b>  | <b>357.26</b>   |
| 14        | <b>Reserve excluding Revaluation reserve as per balance sheet of the previous accounting year</b>                           | <b>0.00</b>    | <b>0.00</b>    | <b>0.00</b>    | <b>0.00</b>     | <b>0.00</b>    | <b>19763.32</b> |
| 15        | <b>i) Earnings Per Share (before extraordinary items)</b>                                                                   |                |                |                |                 |                |                 |
|           | (of Rs.10/- each):                                                                                                          |                |                |                |                 |                |                 |
|           | (a) Basic                                                                                                                   | 16.29          | 7.18           | 17.86          | 23.46           | 42.50          | 67.61           |
|           | (b) Diluted                                                                                                                 | 16.29          | 7.18           | 17.86          | 23.46           | 42.50          | 67.61           |
|           | <b>ii) Earnings Per Share (after extraordinary items)</b>                                                                   |                |                |                |                 |                |                 |
|           | (of Rs.10/- each):                                                                                                          |                |                |                |                 |                |                 |
|           | (a) Basic                                                                                                                   | 16.29          | 7.18           | 17.86          | 23.46           | 42.50          | 67.61           |
|           | (b) Diluted                                                                                                                 | 16.29          | 7.18           | 17.86          | 23.46           | 42.50          | 67.61           |

For Coral Laboratories Limited

*Grish M Dhameja*  
Grish M Dhameja  
Whole Time Director  
DIN : 07798455

*Sushma Kadkade*  
Sushma Kadkade  
Director & CFO  
DIN : 07791735





# CORAL LABORATORIES LTD

AN ISO 9001: 2008 CERTIFIED ORGANIZATION



REGD. OFFICE : #3B, Patanwala Compound, Opp. Shreyas Cinema, L.B.S. Marg, Ghatkopar (West), Mumbai - 400 086. India  
Tel. : +91-22-2500 5245, 2500 8208, 2500 5246. • Fax : +91-22-2500 4893. • E-mail : accounts@corallab.com • Website : www.corallab.com  
CIN NO. L24231MH1997PLC422233

## Statement of Assets and Liabilities as at half year ended September 30, 2025

|                                                                                            |       | (₹ in Lakhs)              |                       |
|--------------------------------------------------------------------------------------------|-------|---------------------------|-----------------------|
| Particulars                                                                                | Notes | As at 30th September 2025 | As at 31st March 2025 |
| <b>A ASSETS</b>                                                                            |       |                           |                       |
| <b>I Non-current assets</b>                                                                |       |                           |                       |
| (a) Property, Plant and Equipment                                                          | 2     | 2312.78                   | 2174.43               |
| (b) Capital Work in Progress                                                               |       | 1350.35                   | 248.15                |
| (c) Investment property                                                                    | 3     | 92.05                     | 92.05                 |
| (d) Other Intangible Assets                                                                | 2     | 6.74                      | 6.74                  |
| (e) Financial Assets                                                                       |       |                           |                       |
| (i) Investments                                                                            | 4     | 2791.98                   | 2480.17               |
| (ii) Trade Receivables                                                                     | 5     | 0.00                      | 0.00                  |
| (iii) Loans                                                                                | 6     | 35.00                     | 35.00                 |
| (iv) Other financial assets                                                                | 7     | 168.30                    | 182.33                |
| (f) Deferred Tax Assets (net)                                                              |       | 0.00                      | 0.00                  |
| (g) Other non-current assets                                                               | 8     | 92.81                     | 73.05                 |
| <b>Total non-current assets</b>                                                            |       | <b>6,850.01</b>           | <b>5,291.93</b>       |
| <b>II Current Assets</b>                                                                   |       |                           |                       |
| (a) Inventories                                                                            | 9     | 1207.77                   | 987.13                |
| (b) Financial Assets                                                                       |       |                           |                       |
| (i) Investments                                                                            | 10    | 2886.36                   | 2754.24               |
| (ii) Trade Receivables                                                                     | 5     | 2635.98                   | 3364.21               |
| (iii) Cash and Cash Equivalents                                                            | 11    | 133.45                    | 340.55                |
| (iv) Bank Balance other than (iii) above                                                   | 12    | 7212.24                   | 7646.15               |
| (v) Loans                                                                                  | 6     | 27.79                     | 23.36                 |
| (vii) Other financial assets                                                               | 7     | 0.00                      | 0.00                  |
| (c) Current Tax Assets (net)                                                               | 13    | 325.58                    | 655.78                |
| (d) Other Current Assets                                                                   | 8     | 2007.90                   | 1883.09               |
| <b>Total Current Assets</b>                                                                |       | <b>16,437.07</b>          | <b>17,654.50</b>      |
| <b>Total Assets</b>                                                                        |       | <b>23,287.09</b>          | <b>22,946.43</b>      |
| <b>B EQUITY &amp; LIABILITIES</b>                                                          |       |                           |                       |
| <b>Equity</b>                                                                              |       |                           |                       |
| (a) Equity Share Capital                                                                   | 14    | 357.26                    | 357.26                |
| (b) Other Equity                                                                           | 15    | 20951.80                  | 19763.32              |
| <b>Total Equity</b>                                                                        |       | <b>21,309.06</b>          | <b>20,120.58</b>      |
| <b>Liabilities</b>                                                                         |       |                           |                       |
| <b>I Non - Current Liabilities</b>                                                         |       |                           |                       |
| (a) Financial Liabilities                                                                  |       |                           |                       |
| (i) Borrowings                                                                             | 16    | 0.00                      | 0.00                  |
| (ii) Trade Payables                                                                        | 17    | 0.00                      | 0.00                  |
| (A) total outstanding dues of micro enterprises and small enterprises                      |       | 0.00                      | 0.00                  |
| (B) total outstanding dues of creditors other than micro enterprises and small enterprises |       | 0.00                      | 0.00                  |
| (iii) Other non-current financial liabilities                                              | 18    | 33.83                     | 33.83                 |
| (b) Provisions                                                                             | 19    | 48.93                     | 40.86                 |
| (c) Deferred Tax Liabilities (Net)                                                         | 20    | 256.42                    | 255.42                |
| (d) Other non-current liabilities                                                          | 21    | 0.00                      | 0.00                  |
| <b>Total Non-Current Liabilities</b>                                                       |       | <b>339.17</b>             | <b>330.11</b>         |
| <b>II Current Liabilities</b>                                                              |       |                           |                       |
| (a) Financial Liabilities                                                                  |       |                           |                       |
| (i) Borrowings                                                                             | 16    | 87.81                     | 355.87                |
| (ii) Trade Payables                                                                        | 17    | 0.00                      |                       |
| (A) total outstanding dues of micro enterprises and small enterprises                      |       | 233.90                    | 271.62                |
| (B) total outstanding dues of creditors other than micro enterprises and small enterprises |       | 363.57                    | 390.65                |
| (iii) Other current financial liabilities                                                  | 18    | 1.00                      | 1.00                  |
| (b) Other Current Liabilities                                                              | 21    | 462.51                    | 473.55                |
| (c) Provisions                                                                             | 19    | 216.07                    | 170.06                |
| (d) Current Tax Liability (net)                                                            | 22    | 274.00                    | 833.00                |
| <b>Total Current Liabilities</b>                                                           |       | <b>1,638.86</b>           | <b>2,495.75</b>       |
| <b>Total Liabilities</b>                                                                   |       | <b>1,978.03</b>           | <b>2,825.85</b>       |
| <b>Total Equity and Liabilities</b>                                                        |       | <b>23,287.09</b>          | <b>22,946.43</b>      |

For Coral Laboratories Limited

Girish M Dhameja  
Whole Time Director  
DIN : 07798455

Sushma Kaddake  
Director & CFO  
DIN : 07791735







# CORAL LABORATORIES LTD

AN ISO 9001: 2008 CERTIFIED ORGANIZATION



REGD. OFFICE : #3B, Patanwala Compound, Opp. Shreyas Cinema, L.B.S. Marg, Ghatkopar (West), Mumbai - 400 086. India  
Tel. : +91-22-2500 5245, 2500 8208, 2500 5246. • Fax : +91-22-2500 4893. • E-mail : accounts@corallab.com • Website : www.corallab.com  
CIN NO. L24231MH1997PLC422233

| Cash Flow Statement for the half year ended 30th September, 2025                            |                                                 | (₹ in lakhs)                                    |
|---------------------------------------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Particulars                                                                                 | For the half year ended 30 Sept, 2025 Unaudited | For the half year ended 30 Sept, 2024 Unaudited |
| <b>A Net cash generated/(used) in Operating Activities</b>                                  |                                                 |                                                 |
| Profit before tax                                                                           | 1,080.94                                        | 2,030.41                                        |
| <b>Adjustments for:</b>                                                                     |                                                 |                                                 |
| Depreciation and amortization expense                                                       | 90.80                                           | 100.30                                          |
| Interest income                                                                             | (247.97)                                        | (196.76)                                        |
| Finance costs                                                                               | 16.06                                           | 3.97                                            |
| Dividend Received                                                                           | (0.77)                                          | (26.32)                                         |
| <b>Operating Profit before working capital changes</b>                                      | <b>939.06</b>                                   | <b>1,911.60</b>                                 |
| <b>Adjustments for:</b>                                                                     |                                                 |                                                 |
| (Increase)/decrease in Trade receivables                                                    | 728.23                                          | (1,082.35)                                      |
| (Increase)/decrease in Other Bank Balance                                                   | 433.91                                          | (398.24)                                        |
| (Increase)/decrease in Inventories                                                          | (220.64)                                        | 219.83                                          |
| (Increase)/decrease in Other Assets (Current & Non Current)                                 | (144.57)                                        | 91.32                                           |
| Increase/(decrease) in Trade Payables                                                       | (64.80)                                         | (885.88)                                        |
| Increase/(decrease) in Other Financial Liability (Current & Non Current)                    | 0.00                                            | 71.45                                           |
| Increase/(decrease) in Other Financial Assets (Current & Non Current)                       | 14.03                                           | (1.28)                                          |
| Increase/(decrease) in provisions (Current & Non Current)                                   | 54.07                                           | 133.53                                          |
| Increase/(decrease) in Other Current Liabilities                                            | (11.04)                                         | 156.51                                          |
| <b>Cash generated from operations</b>                                                       | <b>789.19</b>                                   | <b>(1,695.12)</b>                               |
| Taxes paid (Net of refunds)                                                                 | 470.56                                          | 321.16                                          |
| <b>Net cash flow from operating activities</b>                                              | <b>1,257.69</b>                                 | <b>(104.69)</b>                                 |
| <b>B Net cash generated/(used) from Investing Activities</b>                                |                                                 |                                                 |
| Purchases / (Sale) of Property, Plant & Equipment                                           | (229.15)                                        | (16.12)                                         |
| Change in Capital WIP                                                                       | (1,102.20)                                      |                                                 |
| Interest received                                                                           | 247.97                                          | 196.76                                          |
| Dividend received                                                                           | 0.77                                            | 26.32                                           |
| Purchase / Sale of investments                                                              | -                                               | (42.94)                                         |
| OCI Income                                                                                  | (93.63)                                         | (95.45)                                         |
| <b>Net Cash generated/ (used) in Investing Activities</b>                                   | <b>(1,176.24)</b>                               | <b>68.57</b>                                    |
| <b>C Net cash generated/(used) from Financing Activities</b>                                |                                                 |                                                 |
| Acceptance / (Repayment) of borrowings & loans                                              | (272.49)                                        | 1.49                                            |
| Payment of Dividend                                                                         | -                                               | (71.45)                                         |
| Finance costs                                                                               | (16.06)                                         | (3.97)                                          |
| <b>Net cash flow from / (used in) financing activities</b>                                  | <b>(288.54)</b>                                 | <b>(73.93)</b>                                  |
| <b>D Net cashflow generated / (used)</b>                                                    | <b>(207.09)</b>                                 | <b>(110.05)</b>                                 |
| Cash & Cash Equivalents as at beginning of the year                                         | 340.55                                          | 207.14                                          |
| Effect of exchange differences on restatement of foreign currency Cash and cash equivalents |                                                 | -                                               |
| <b>Cash &amp; Cash equivalents as at end of the year</b>                                    | <b>133.45</b>                                   | <b>97.10</b>                                    |

The above Statement of Cash Flows has been prepared under the 'Indirect Method' as set out in the Ind AS 7 on Statement of Cash Flows

For Coral Laboratories Limited

Girish M Dhameja  
Whole Time Director  
DIN : 07798455

Sushma Kadkade  
Director & CFO  
DIN : 07791735





# CORAL LABORATORIES LTD

AN ISO 9001: 2008 CERTIFIED ORGANIZATION



REGD. OFFICE : #3B, Patanwala Compound, Opp. Shreyas Cinema, L.B.S. Marg, Ghatkopar (West), Mumbai - 400 086. India  
Tel. : +91-22-2500 5245, 2500 8208, 2500 5246. • Fax : +91-22-2500 4893. • E-mail : accounts@corallab.com • Website : www.corallab.com  
CIN NO. L24231MH1997PLC422233

## Notes:

- <sup>1</sup> The Unaudited Standalone Financial Results for the quarter and half year ended September 30, 2025 have been reviewed by the Audit Committee and were approved by the Board of Directors of the Company at their respective meetings held on November 14, 2025
- <sup>2</sup> This statement is as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These audited financial results of the Company were prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ('IND AS') and other accounting principles generally accepted in India and guidelines issued by the Securities Exchange Board of India ("SEBI").
- <sup>3</sup> The Statutory Auditors have carried out the Limited Review of the financial results of the Company.
- <sup>4</sup> The Company has only one segment viz. "Formulations" as per Accounting Standard 17 of ICAI.
- <sup>5</sup> During the quarter and half year ended September 30, 2025, the Company do not have any subsidiary/associate/joint venture company(ies).
- <sup>6</sup> Corresponding quarter/year figures have been regrouped/reclassified wherever necessary to confirm to the classification of the current period.

For Coral Laboratories Limited

Girish M Dhameja  
Whole Time Director  
DIN : 07798455

Sushma Kadkade  
Director & CFO  
DIN : 07791735

Place : Mumbai

Date : Nov 14, 2025